Advertisement

Effect of prevention and treatment of murine acute viral myocarditis and protection of lymphoid organ atrophy with xinkang oral liquid Open image in new window

  • Su-jun Wan
  • Hong Zhao
  • Jian-nong Li
  • Li-xia Wang
  • Xia-zhen Huang
  • Hong-shan Chen
Article
  • 15 Downloads

Abstract

Objective

The effect of prevention and treatment of Xinkang oral liquid, (
, XKOL) on experimental coxsackievirus B3 (CVB3) myocarditis mice model were investigated.

Methods

The mice were inoculated intraperitoneally with 0.3 ml of 105 TCID50 of CVB3 to induce acute viral myocarditis model. These mice were divided into model control group (Group A), prevention high dosage group (Group B) and prevention low dosage group (Group C), treatment high dosage group (Group D) and treatment low dosage group (Group E), respectively. In addition, XKOL control group (Group F) and normal control group (Group G) were not infected with CVB3 intraperitoneally. The administration of XKOL in Group B and C began 2 days before virus infection. All animals were sacrificed on day 20 for evaluation.

Results

Histological examination showed extensive myocardial necrosis and cell infiltration in most of Group A mice, but necrosis and cell infiltration were less severe in Group B,C,D and E mice. Thymus weight in Group B,C,D and E mice were heavier and less cell depletion occurred than those in Group A.

Conclussion

The XKOL could effectively inhibit myocardial CVB3 replication, reduce the myocardial inflammatory response, lower incidence rate of myocarditis and prevent the disease associated lymphoid organ atrophy in this animal models.

Key Words

Xinkang oral liquid coxsackievirus B3 myocarditis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. l.
    GS Sainani, MP Dekate and CP Rao. Heart disease caused by coxsackievirus B infection. British Heart J 1975, 37: 819.CrossRefGoogle Scholar
  2. 2.
    M Herzum, SA Huber, R Weller, et al. Treatment of experimental murine coxsackie B3 myocarditis. Eur Heart J 1991; 12(suppl D): 220.Google Scholar
  3. 3.
    C Kishimoto, CS Crumpacker, WH Abelmann. Prevention of murine coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leukocyte interferona A/D. Cardiovascular Res 1988; 22: 732.CrossRefGoogle Scholar
  4. 4.
    NV Houten and SA Huber. Genetics of coxsackie B3 myocarditis. Eur Heart J 1991; 12(Suppl D): 108–112.PubMedGoogle Scholar
  5. 5.
    D Matteucci, A Toniolo, PG Conaldi, et al. Systemic lymphoid atrophy in coxsackie virus B3 infected mice. J Infect Dis 1985; 151: 110.Google Scholar

Copyright information

© The Chinese Journal of Integrated Traditional and Western Medicine Press 2002

Authors and Affiliations

  • Su-jun Wan
    • 1
  • Hong Zhao
    • 2
  • Jian-nong Li
    • 3
  • Li-xia Wang
    • 1
  • Xia-zhen Huang
    • 1
  • Hong-shan Chen
    • 3
  1. 1.The 2nd Department of Basic MedicineGuang’anmen Hospital, China Academy of Traditional Chinese MedicineBeijing
  2. 2.Fuwai HospitalChinese Academy of Medical SciencesChina
  3. 3.Institute of Medical and Biological TechniqueChinese Academy of Medical SciencesChina

Personalised recommendations